Chemical-induced autoimmune reactions and spanish toxic oil syndrome. Focus on hydantoins and related compounds

References

• Mackay I. R. Autoimmunity in relation to lupus erythematosus. Dubois' Lupus Erythematosus, 3rd ed., D. J. Wallace, E. L. Dubois. Lea & Febiger, Philadelphia 1987; 44
   Google Scholar
• Cohen I. R., Cooke A. Natural autoantibodies might prevent autoimmune disease. Immunology Today 1986; 7: 363–364
   PubMedGoogle Scholar
• Wallace D. J., Dubois E. L. Definition, classification, and epidemiology of systemic lupus erythematosus. Dubois' Lupus Erythematosus, 3rd ed., D. J. Wallace, E. L. Dubois. Lea & Febiger, Philadelphia 1987; 15
   Google Scholar
• Hahn B. H. Animal models of systemic lupus erythematosus. Dubois' Lupus Erythematosus, 3rd ed., D. J. Wallace, E. L. Dubois. Lea & Febiger, Philadelphia 1987; 130
   Google Scholar
• Fleischmajer R., Perlish J. S., Reeves J. R.T. Cellular infiltrates in scleroderma skin. Arthritis Rheum. 1977; 20: 975–984
   PubMed Web of Science ®Google Scholar
• Gleichmann E., Pals S. T., Rolink A. G., Radaszkiewicz T., Gleichmann H. Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. Immunology Today 1984; 5: 324–332
   PubMedGoogle Scholar
• Welsh K. I., Black C. M. Genetic aspects of the acquired connective tissue diseases. Sem. Dermatol. 1985; 4: 152–163
   Google Scholar
• Dubois E. L., Wallace D. J. Drugs that exacerbate and induce systemic lupus erythematosus. Dubois' Lupus Erythematosus, 3rd ed., D. J. Wallace, E. L. Dubois. Lea & Febiger, Philadelphia 1987; 450
   Google Scholar
• Homsy J., Morrow W. J.W., Levy J. A. Nutrition and autoimmunity: a review. Clin. exp. Immunol. 1986; 65: 473–488
   PubMed Web of Science ®Google Scholar
• Zürcher K., Krebs A. Cutaneous Side Effects of Systemic Drugs. A Commentated Synopsis of Today's Drugs. Karger, Basel 1980; 165
   Google Scholar
• Gosselin R. E., Smith R. P., Hodge H. C. Clinical Toxicology of Commercial Products, 5th ed. Williams and Wilkins, Baltimore 1984; IV–97
   Google Scholar
• Mali J. H.W., Malten K. E. The epidemic of polymorph toxic erythema in the Netherlands in 1960. The so-called margarine disease. Acta derm.-venereol. 1966; 46: 123–135
   PubMed Web of Science ®Google Scholar
• Review of investigations and findings. Toxic Oil Syndrome: Mass Food Poisoning in Spain, P. Grandjean, S. Tarkowski. WHO Regional Office for Europe, Copenhagen 1984; 3
   Google Scholar
• Aldridge W. N. Toxic oil syndrome. Human Toxicol. 1985; 4: 231–235
   PubMedGoogle Scholar
• Toxic Epidemic Syndrome Study Group. Toxic epidemic syndrome, Spain, 1981. Lancet 1982; ii: 697–702
   Google Scholar
• Martinez-Tello F. J., Navas-Palacios J. J., Ricoy J. R., Gil-Martin R., Conde-Zurita J. M., Colina-Ruiz Delgado F., Teller I., Cabello A., Madero-Garcia S. Pathology of a new toxic syndrome caused by ingestion of adulterated oil in Spain. Virchows Arch. (Pathol. Anat.) 1982; 397: 261–285
   PubMed Web of Science ®Google Scholar
• Alonso-Ruiz A., Zea-Mendoza A. C., Salazar-Vallinas J. M., Rocamora-Ripoll A., Beltran-Gutierrez J. Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma. Sem. Arthritis Rheum. 1986; 15: 200–212
   PubMed Web of Science ®Google Scholar
• Fernandez-Segoviano P., Esteban A., Martinez-Cabruja R. Pulmonary vascular lesions in the toxic oil syndrome in Spain. Thorax 1983; 38: 724–729
   PubMed Web of Science ®Google Scholar
• Gomez-Reino J. J. Immune system disorders associated with adulterated cooking oil. Immunotoxicology, A. Berlin, J. Dean, M. H. Draper, E. M.B. Smith, F. Spreafico. Martinus Nijhoff Publishers, Dordrecht 1987; 376
   Google Scholar
• Gutierrez C., Gaspar L., Muro R., Kreisler M., Ferriz P. Autoimmunity in patients with Spanish toxic oil syndrome. Lancet 1983; i: 644
   Google Scholar
• Vicario J. L., Serrano-Rios M., San-Andres F., Arnaiz-Villena A. HLA-DR3, DR4 increase in chronic stage of Spanish oil disease. Lancet 1982; i: 276
   Google Scholar
• Tabuenca J. M. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 1981; ii: 567–568
   Google Scholar
• Kilbourne E. M., Rigau-Perez J. G., Heath C. W., Zack M. M., Falk H., Martin-Marcos M., De Carlos A. Clinical epidemiology of toxic-oil syndrome. Manifestations of a new illness. N. Engl. J. Med. 1983; 309: 1408–1414
   PubMed Web of Science ®Google Scholar
• Rigau-Perez J. G., Perez-Alvarez L., Duenas-Castro S., Choi K., Thacker S. B., German J. C., Gonsalez-de-Andres G., Canada-Royo L., Perez-Gallardo F. Epidemiological investigation of an oil associated pneumonic paralytic eosinophilic syndrome in Spain. Am. J. Epidemiol. 1984; 119: 250–260
   PubMed Web of Science ®Google Scholar
• Posada M., Castro M., Kilbourne E. M., Diaz de Rojas F., Abaitua I., Tabuenca J. M., Vioque A. Toxic oil syndrome: case reports associated with the ITH oil refinery in Sevilla. Fd. Chem. Toxic. 1987; 25: 87–90
   PubMed Web of Science ®Google Scholar
• Kammüller M. E., Seinen W. On the possible etiological role of isothiocyanate-derived heterocyclic compounds in the pathogenesis of Spanish toxic oil syndrome and other allergic and autoimmune-like diseases – hypothesis. Proceedings of Euro Food Tox II, Zürich, 1986, 300
   Google Scholar
• Kammüller M. E., Seinen W. Toxicology of naturally occurring isothiocyanates in the human diet – a short review. Human Toxicol., (in press)
   Google Scholar
• Kammüller M. E., Penninks A. H., Seinen W. Spanish toxic oil syndrome is a chemically induced GVHD-like epidemic. Lancet 1984; i: 1174–1175
   Google Scholar
• Kammüller M. E., Penninks A. H., De Bakker J. M., Thomas C., Bloksma N., Seinen W. An experimental approach to chemically induced systemic (auto) immune alterations: the Spanish toxic oil syndrome as an example. Mechanisms of Cell Injury: Implications for Human Health. Dahlem Konferenzen, B. A. Fowler. John Wiley & Sons, Chichester 1987; 175
   Google Scholar
• Schmidt D. Adverse Effects of Antiepileptic Drugs. Raven Press, New York 1982; 42
   Google Scholar
• Pilcher J. D., Gerstenberger H. J. Treatment of chorea with phenyl-ethyl-hydantoin. Am. J. Dis. Child. 1930; 40: 1239–1249
   Google Scholar
• Michael J. R., Rudin M. L. Acute pulmonary disease caused by phenytoin. Ann. Intern. Med. 1981; 95: 452–454
   PubMed Web of Science ®Google Scholar
• Fruchter L., Laptook A. Diphenylhydantoin hypersensitivity reaction with interstitial pulmonary infiltrates and hypereosinophilia. Ann. Allergy 1981; 47: 453–455
   PubMedGoogle Scholar
• Gams R. A., Neal J. A., Conrad F. G. Hydantoin-induced pseudopseudolymphoma. Ann. Intern. Med. 1968; 69: 557–568
   PubMed Web of Science ®Google Scholar
• Harney J., Glasberg M. R. Myopathy and hypersensitivity to phenytoin. Neurology 1983; 33: 790–791
   PubMed Web of Science ®Google Scholar
• Mastaglia F. L., Argov Z. Immunologically mediated drug-induced neuromuscular disorders. Pseudo-Allergic Reactions, Involvement of Drugs and Chemicals. Karger, Basel 1982; 3: 62
   Google Scholar
• Holmberg L., Boman G., Böttiger L. E., Eriksson B., Spross R., Wessling A. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am. J. Med. 1980; 69: 733–738
   PubMed Web of Science ®Google Scholar
• Searles R. P., Plymate S. R., Troup G. M. Familial thioamide-induced lupus syndrome in thyrotoxicosis. J. Rheumatol. 1981; 8: 498–500
   PubMed Web of Science ®Google Scholar
• Seidman D. S., Livni E., Ilie B., Blum J. Propylthiouracil-induced cholestatic jaundice. Clin. Toxicol. 1986; 24: 353–360
   Web of Science ®Google Scholar
• Gibson P. C., Quinlan J. T. Periarteritis nodosa in thiourea therapy. Lancet 1945; ii: 108–110
   Google Scholar
• Zangemeister W. H., Weisner B. Eine der progressiven Sklerodermie ähnliche Erkrankung als Folge der antikonvulsiven Therapie. Fortschr. Neurol. Psychiat. 1977; 45: 501–507
   Google Scholar
• Teoh P. C., Chan H. L. Lupus-scleroderma syndrome induced by ethosuximide. Archs. Dis. Childh. 1975; 50: 658–661
   PubMed Web of Science ®Google Scholar
• Gurtner H. P. Pulmonary hypertension, plexogenic pulmonary artheriopathy and the appetite depressant drug aminorex: post or propter. Bull. europ. Physiopath. resp. 1979; 15: 897–923
   PubMedGoogle Scholar
• Kay J. M., Smith P., Heath D. Aminorex and the pulmonary circulation. Thorax 1971; 26: 262–270
   PubMed Web of Science ®Google Scholar
• MacLeod G., Seyyedain-Ardebili M. Natural and simulated meat flavors (with particular reference to beef). CRC Crit. Rev. Food Sci. Nutr. 1981; 14: 309–437
   Google Scholar
• Corman L. C. The role of the diet in animal models of systemic lupus erythematosus: possible implications for human lupus. Sem. Arthritis Rheum. 1985; 15: 61–69
   PubMed Web of Science ®Google Scholar
• Spielberg S. P., Gordon G. B., Blake D. A., Goldstein D. A., Herlong H. F. Predisposition to phenytoin hepatotoxicity assessed in vitro. N. Engl. J. Med. 1981; 305: 722–727
   PubMed Web of Science ®Google Scholar
• Mullen P. W., Queiroz M. L.S. Phenytoin and humoral immunity: background and a pharmacokinetic interpretation of recent findings. Advances in Immunopharmacology, J. W. Hadden, L. Chedid, P. Dukor, F. Spreafico, D. Willoughby. Pergamon Press, Oxford 1983; 2: 3
   Google Scholar
• Wedlund P. J., Aslanian W. S., Jacqz E., McAllister C. B., Branch R. A., Wilkinson G. R. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J. Pharmacol. Exp. Ther. 1985; 234: 662–669
   PubMed Web of Science ®Google Scholar
• Jacqz E., Hall S. D., Branch R. A. Genetically determined polymorphisms in drug oxidation. Hepatology 1986; 6: 1020–1032
   PubMed Web of Science ®Google Scholar
• Krüger G. Effects of dilantin in mice. I. Changes in the lymphoreticular tissue after acute exposure. Virchows Arch. (Pathol. Anat.) 1970; 349: 297–311
   Web of Science ®Google Scholar
• Tucker A. N., Hong L., Boorman G. A., Pung O., Luster M. I. Alteration of bone marrow cell cycle kinetics by diphenylhydantoin: relationship to folate utilization and immune function. J. Pharmacol. Exp. Ther. 1985; 234: 57–62
   PubMed Web of Science ®Google Scholar
• Margaretten N. C., Warren R. P. Effect of phenytoin on antibody production: use of a murine model. Epilepsia 1987; 28: 77–80
   PubMed Web of Science ®Google Scholar
• Aucoin D. P., Peterson M. E., Hurvitz A. I., Drayer D. E., Lahita R. G., Quimby P. W., Reidenberg M. M. Propylthiouracil-induced immune-mediated disease in the cat. J. Pharmacol. Exp. Ther. 1985; 234: 13–18
   PubMed Web of Science ®Google Scholar
• Malinow M. R., Bardana E. J., Pirofsky B., Craig S., Mc-Laughlin P. Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: role of a non-protein amino acid. Science 1982; 216: 415–417
   PubMed Web of Science ®Google Scholar
• Alarcón-Segovia D., Diaz-Jouanen E. Lupus subsets: relationships to genetic and environmental factors. Sem. Arthritis Rheum. 1980; 4: 18–24
   Google Scholar
• Theofilopoulos A. N., Dixon F. J. Murine models of systemic lupus erythematosus. Adv. Immunol. 1985; 37: 269–390
   PubMed Web of Science ®Google Scholar
• Ford W. L. Measurement of graft-versus-host activity. Handbook of Experimental Immunology, 3rd ed., D. M. Weir. Blackwell Scientific Publications, Oxford 1978; 30.1
   Google Scholar
• Gleichmann H. Studies on the mechanism of drug sensitization: T-cell-dependent popliteal lymph node reaction to diphenylhydantoin. Clin. Immunol. Immunopathol. 1981; 18: 203–211
   PubMedGoogle Scholar
• Hurtenbach U., Gleichmann H., Nagata N., Gleichmann E. Immunity to D-penicillamine: genetic, cellular, and chemical requirements for induction of popliteal lymph node enlargement in the mouse. J. Immunol. 1987; 139: 411–416
   PubMed Web of Science ®Google Scholar
• Wagner C. R., Vetto R. M., Burger D. R. The mechanisms of antigen presentation by endothelial cells. Immunobiol 1984; 168: 453–469
   PubMed Web of Science ®Google Scholar
• Camus P., Jeannin L. The diseased lung and drugs. Arch. Toxicol. 1984; 7: 66–87, Suppl.
   Google Scholar
• Fleischmajer R., Perlish J. S., Duncan M. Scleroderma, A model for fibrosis (editorial). Arch. Dermatol. 1983; 119: 957–962
   PubMed Web of Science ®Google Scholar
• Tomlinson I. W., Jayson M. I.V. Systemic sclerosis after therapy with appetite suppressants. J. Rheumatol. 1984; 11: 254
   PubMed Web of Science ®Google Scholar